Viral Therapeutics, Inc. has operated as a developer and manufacturer of recombinant proteins since 1995. With its strategy to license and develop technology, as well as a highly talented and experienced staff, VTI became a leading supplier of recombinant human proteins for research and diagnostic use.
From these competencies, VTI continues to build a proprietary product portfolio for the biotechnology and pharmaceutical industries. Employing a revenue-based strategy, coupled with licensing and strategic partnerships, we have built a biotechnology company that provides support for over 55 clients and partners worldwide.
VTI has either licensed or owned over 110 patents and patent applications.
Intellectual Property Portfolio
- VagiPrev exclusive license worldwide rights
- ViruSorb exclusive license worldwide rights
- Protein manufacturing technology (70 Patents)
- Herpes HSV recombinant proteins license (25 Patents Chiron)
- Pharmacogenomics portfolio: 11 Final Filings Encompassing 34 Diseases, 7 Genes, and 336 SNP-Disease Associations
Operations span several areas of products and services:
BioPharma: Proprietary drugs and pharmacogenomics for drug discovery, prognostic indicators of disease and adverse drug responses.
BioProducts: Recombinant proteins used in diagnostic and research applications.
BioServices: Contract services for the development of therapeutic or diagnostic recombinant proteins.